Nivolumab With or Without Ipilimumab Plus Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)
J. Clin. Oncol 2022 Apr 27;[EPub Ahead of Print], IM Chen, JS Johansen, S Theile, JX Hjaltelin, SI Novitski, S Brunak, JP Hasselby, GL Willemoe, T Lorentzen, K Madsen, BV Jensen, EE Wilken, P Geertsen, C Behrens, C Nolsoe, KL Hermann, IM Svane, D NielsenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.